{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:42:58Z","timestamp":1793817778600,"version":"4.6.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073147"],"award-info":[{"award-number":["82073147"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472969"],"award-info":[{"award-number":["82472969"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82241233"],"award-info":[{"award-number":["82241233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"publisher","award":["CSTB2023NSCQ-JQX0026"],"award-info":[{"award-number":["CSTB2023NSCQ-JQX0026"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cell Biol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41556-025-01840-5","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:03:06Z","timestamp":1767780186000},"page":"338-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive resistance to immunotherapy in non-small-cell lung cancer"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6043-6234","authenticated-orcid":false,"given":"Lei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Degao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenFeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouxia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-8565","authenticated-orcid":false,"given":"Haoyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2465-0337","authenticated-orcid":false,"given":"Xindong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-5395","authenticated-orcid":false,"given":"Qingzhu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-8512","authenticated-orcid":false,"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-7630","authenticated-orcid":false,"given":"Qian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"1840_CR1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck, M. et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37, 537\u2013546 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1840_CR2","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1840_CR3","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"1840_CR4","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50. J. Clin. Oncol. 39, 2339\u20132349 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1840_CR5","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino, M. C. et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 Study. J. Clin. Oncol. 41, 1992\u20131998 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1840_CR6","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.21.02885","volume":"41","author":"G de Castro Jr.","year":"2023","unstructured":"de Castro, G. Jr. et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score >\/= 1% in the KEYNOTE-042 study. J. Clin. Oncol. 41, 1986\u20131991 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1840_CR7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello, S. et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J. Clin. Oncol. 41, 1999\u20132006 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1840_CR8","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","volume":"17","author":"M Mino-Kenudson","year":"2022","unstructured":"Mino-Kenudson, M. et al. Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee. J. Thorac. Oncol. 17, 1335\u20131354 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"1840_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"1840_CR10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41586-024-07529-3","volume":"630","author":"JE Bader","year":"2024","unstructured":"Bader, J. E. et al. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature 630, 968\u2013975 (2024).","journal-title":"Nature"},{"key":"1840_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495\u2013499 (2017).","journal-title":"Nature"},{"key":"1840_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","volume":"40","author":"K Kersten","year":"2022","unstructured":"Kersten, K. et al. Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Cancer Cell 40, 624\u2013638 (2022).","journal-title":"Cancer Cell"},{"key":"1840_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"J Waibl Polania","year":"2025","unstructured":"Waibl Polania, J. et al. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity 58, 232\u2013246 (2025).","journal-title":"Immunity"},{"key":"1840_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn8608","volume":"386","author":"A Kuratani","year":"2024","unstructured":"Kuratani, A. et al. Platelet factor 4-induced TH1-Treg polarization suppresses antitumor immunity. Science 386, eadn8608 (2024).","journal-title":"Science"},{"key":"1840_CR15","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","volume":"54","author":"K Mulder","year":"2021","unstructured":"Mulder, K. et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 54, 1883\u20131900 (2021).","journal-title":"Immunity"},{"key":"1840_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma, R. Y., Black, A. & Qian, B. Z. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 43, 546\u2013563 (2022).","journal-title":"Trends Immunol."},{"key":"1840_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s43018-025-00909-2","volume":"6","author":"R Jin","year":"2025","unstructured":"Jin, R., Neufeld, L. & McGaha, T. L. Linking macrophage metabolism to function in the tumor microenvironment. Nat. Cancer 6, 239\u2013252 (2025).","journal-title":"Nat. Cancer"},{"key":"1840_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","volume":"593","author":"BI Reinfeld","year":"2021","unstructured":"Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282\u2013288 (2021).","journal-title":"Nature"},{"key":"1840_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"1840_CR20","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","volume":"57","author":"A De Leo","year":"2024","unstructured":"De Leo, A. et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity 57, 1105\u20131123 (2024).","journal-title":"Immunity"},{"key":"1840_CR21","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.cmet.2021.09.002","volume":"33","author":"SM Morrissey","year":"2021","unstructured":"Morrissey, S. M. et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 33, 2040\u20132058 (2021).","journal-title":"Cell Metab."},{"key":"1840_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02064-1","volume":"23","author":"X Chu","year":"2024","unstructured":"Chu, X., Tian, Y. & Lv, C. Decoding the spatiotemporal heterogeneity of tumor-associated macrophages. Mol. Cancer 23, 150 (2024).","journal-title":"Mol. Cancer"},{"key":"1840_CR23","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1158\/0008-5472.CAN-20-0069","volume":"80","author":"X Zheng","year":"2020","unstructured":"Zheng, X. et al. Spatial density and distribution of tumor-associated macrophages predict survival in non-small cell lung carcinoma. Cancer Res. 80, 4414\u20134425 (2020).","journal-title":"Cancer Res."},{"key":"1840_CR24","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","volume":"56","author":"A Sattiraju","year":"2023","unstructured":"Sattiraju, A. et al. Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression. Immunity 56, 1825\u20131843 (2023).","journal-title":"Immunity"},{"key":"1840_CR25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","volume":"42","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization. Cancer Cell 42, 815\u2013832 (2024).","journal-title":"Cancer Cell"},{"key":"1840_CR26","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ van Elsas","year":"2024","unstructured":"van Elsas, M. J. et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell 42, 1032\u20131050 (2024).","journal-title":"Cancer Cell"},{"key":"1840_CR27","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1840_CR28","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1840_CR29","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles, J. R., Globig, A. M., Kaech, S. M. & Wherry, E. J. CD8+ T cells in the cancer-immunity cycle. Immunity 56, 2231\u20132253 (2023).","journal-title":"Immunity"},{"key":"1840_CR30","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/cmdc.201600276","volume":"11","author":"H Siebeneicher","year":"2016","unstructured":"Siebeneicher, H. et al. Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. ChemMedChem 11, 2261\u20132271 (2016).","journal-title":"ChemMedChem"},{"key":"1840_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.4155\/fmc-2021-0071","volume":"13","author":"S Cao","year":"2021","unstructured":"Cao, S., Chen, Y., Ren, Y., Feng, Y. & Long, S. GLUT1 biological function and inhibition: research advances. Future Med. Chem. 13, 1227\u20131243 (2021).","journal-title":"Future Med. Chem."},{"key":"1840_CR32","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.ccell.2022.10.008","volume":"40","author":"S Salcher","year":"2022","unstructured":"Salcher, S. et al. High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer. Cancer Cell 40, 1503\u20131520 (2022).","journal-title":"Cancer Cell"},{"key":"1840_CR33","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu, A. et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature 637, 1207\u20131217 (2025).","journal-title":"Nature"},{"key":"1840_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s43018-022-00356-3","volume":"3","author":"T Chu","year":"2022","unstructured":"Chu, T., Wang, Z., Pe\u2019er, D. & Danko, C. G. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat. Cancer 3, 505\u2013517 (2022).","journal-title":"Nat. Cancer"},{"key":"1840_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova, N. N., Zhu, J. & Thompson, C. B. The hallmarks of cancer metabolism: still emerging. Cell Metab. 34, 355\u2013377 (2022).","journal-title":"Cell Metab."},{"key":"1840_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18020-8","volume":"11","author":"Q Wu","year":"2020","unstructured":"Wu, Q. et al. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nat. Commun. 11, 4205 (2020).","journal-title":"Nat. Commun."},{"key":"1840_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41420-024-02106-z","volume":"10","author":"ZA Miller","year":"2024","unstructured":"Miller, Z. A. et al. GLUT1 inhibitor BAY-876 induces apoptosis and enhances anti-cancer effects of bitter receptor agonists in head and neck squamous carcinoma cells. Cell Death Discov. 10, 339 (2024).","journal-title":"Cell Death Discov."},{"key":"1840_CR38","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/cancers16071399","volume":"16","author":"L Guo","year":"2024","unstructured":"Guo, L. et al. Inhibition of carbohydrate metabolism potentiated by the therapeutic effects of oxidative phosphorylation inhibitors in colon cancer cells. Cancers 16, 1399 (2024).","journal-title":"Cancers"},{"key":"1840_CR39","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/cas.13995","volume":"110","author":"H Sawayama","year":"2019","unstructured":"Sawayama, H. et al. Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer. Cancer Sci. 110, 1705\u20131714 (2019).","journal-title":"Cancer Sci."},{"key":"1840_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123178","volume":"319","author":"K Wang","year":"2025","unstructured":"Wang, K. et al. Sonodynamic activated nanoparticles with Glut1 inhibitor and cystine-containing polymer stimulate disulfidptosis for improved immunotherapy in bladder cancer. Biomaterials 319, 123178 (2025).","journal-title":"Biomaterials"},{"key":"1840_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202310163","volume":"11","author":"T Li","year":"2024","unstructured":"Li, T. et al. Metabolism\/immunity dual-regulation thermogels potentiating immunotherapy of glioblastoma through lactate-excretion inhibition and PD-1\/PD-L1 blockade. Adv. Sci. 11, e2310163 (2024).","journal-title":"Adv. Sci."},{"key":"1840_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42883-2","volume":"14","author":"X Ren","year":"2023","unstructured":"Ren, X. et al. Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer. Nat. Commun. 14, 7021 (2023).","journal-title":"Nat. Commun."},{"key":"1840_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale, I., Manic, G., Coussens, L. M., Kroemer, G. & Galluzzi, L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36\u201350 (2019).","journal-title":"Cell Metab."},{"key":"1840_CR44","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7150\/thno.51777","volume":"11","author":"D Chen","year":"2021","unstructured":"Chen, D., Zhang, X., Li, Z. & Zhu, B. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics 11, 1016\u20131030 (2021).","journal-title":"Theranostics"},{"key":"1840_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07767-w","volume":"9","author":"Q Jia","year":"2018","unstructured":"Jia, Q. et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat. Commun. 9, 5361 (2018).","journal-title":"Nat. Commun."},{"key":"1840_CR46","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.immuni.2022.09.002","volume":"55","author":"S Liu","year":"2022","unstructured":"Liu, S. et al. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity 55, 1940\u20131952 (2022).","journal-title":"Immunity"},{"key":"1840_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100856","volume":"3","author":"B Yang","year":"2022","unstructured":"Yang, B. et al. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis. Cell Rep. Med. 3, 100856 (2022).","journal-title":"Cell Rep. Med."},{"key":"1840_CR48","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-019-0592-2","volume":"25","author":"K Joshi","year":"2019","unstructured":"Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat. Med. 25, 1549\u20131559 (2019).","journal-title":"Nat. Med."},{"key":"1840_CR49","doi-asserted-by":"publisher","first-page":"e20242282","DOI":"10.1084\/jem.20242282","volume":"222","author":"M Tanaka","year":"2025","unstructured":"Tanaka, M. et al. Tumor cell heterogeneity drives spatial organization of the intratumoral immune response. J. Exp. Med. 222, e20242282 (2025).","journal-title":"J. Exp. Med."},{"key":"1840_CR50","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","volume":"49","author":"J Li","year":"2018","unstructured":"Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49, 178\u2013193 e7 (2018).","journal-title":"Immunity"},{"key":"1840_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55330-7","volume":"16","author":"L Klein","year":"2025","unstructured":"Klein, L. et al. Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Nat. Commun. 16, 335 (2025).","journal-title":"Nat. Commun."},{"key":"1840_CR52","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","volume":"184","author":"M Di Pilato","year":"2021","unstructured":"Di Pilato, M. et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell 184, 4512\u20134530 (2021).","journal-title":"Cell"},{"key":"1840_CR53","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"1840_CR54","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","volume":"41","author":"P Meiser","year":"2023","unstructured":"Meiser, P. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41, 1498\u20131515 (2023).","journal-title":"Cancer Cell"},{"key":"1840_CR55","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41586-024-08257-4","volume":"637","author":"A Elewaut","year":"2025","unstructured":"Elewaut, A. et al. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. Nature 637, 716\u2013725 (2025).","journal-title":"Nature"},{"key":"1840_CR56","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","volume":"185","author":"P Baldominos","year":"2022","unstructured":"Baldominos, P. et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell 185, 1694\u20131708 (2022).","journal-title":"Cell"},{"key":"1840_CR57","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.ccell.2025.07.014","volume":"43","author":"D Chen","year":"2025","unstructured":"Chen, D. et al. DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. Cancer Cell 43, 1758\u20131775 (2025).","journal-title":"Cancer Cell"},{"key":"1840_CR58","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen, A. et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389\u20131399 (2023).","journal-title":"Nat. Med."},{"key":"1840_CR59","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41590-024-01792-2","volume":"25","author":"JH Chen","year":"2024","unstructured":"Chen, J. H. et al. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nat. Immunol. 25, 644\u2013658 (2024).","journal-title":"Nat. Immunol."},{"key":"1840_CR60","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.ccell.2021.10.008","volume":"39","author":"J Duraiswamy","year":"2021","unstructured":"Duraiswamy, J. et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell 39, 1623\u20131642 (2021).","journal-title":"Cancer Cell"},{"key":"1840_CR61","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"1840_CR62","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"1840_CR63","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","volume":"16","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. J. Thorac. Oncol. 16, 2109\u20132120 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1840_CR64","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1840_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).","journal-title":"Genome Biol."},{"key":"1840_CR66","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"1840_CR67","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","volume":"591","author":"R Zappasodi","year":"2021","unstructured":"Zappasodi, R. et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature 591, 652\u2013658 (2021).","journal-title":"Nature"},{"key":"1840_CR68","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017).","journal-title":"Lancet"},{"key":"1840_CR69","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype\u2013immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248\u2013262 (2017).","journal-title":"Cell Rep."},{"key":"1840_CR70","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1016\/j.cell.2023.11.003","volume":"186","author":"E Zormpas","year":"2023","unstructured":"Zormpas, E., Queen, R., Comber, A. & Cockell, S. J. Mapping the transcriptome: realizing the full potential of spatial data analysis. Cell 186, 5677\u20135689 (2023).","journal-title":"Cell"},{"key":"1840_CR71","doi-asserted-by":"publisher","unstructured":"Wang, L. & Chu, H. Data for \u2018SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive immunotherapy resistance in non-small cell lung cancer\u2019. Zenodo https:\/\/doi.org\/10.5281\/zenodo.15605493 (2025).","DOI":"10.5281\/zenodo.15605493"}],"updated-by":[{"DOI":"10.1038\/s41556-026-01874-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000}}],"container-title":["Nature Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41556-025-01840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41556-025-01840-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41556-025-01840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:02:36Z","timestamp":1770994956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41556-025-01840-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1038\/s41556-025-01840-5","relation":{},"ISSN":["1465-7392","1476-4679"],"issn-type":[{"value":"1465-7392","type":"print"},{"value":"1476-4679","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41556-026-01874-3","URL":"https:\/\/doi.org\/10.1038\/s41556-026-01874-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}